0000919574-20-005630.txt : 20200831 0000919574-20-005630.hdr.sgml : 20200831 20200831193300 ACCESSION NUMBER: 0000919574-20-005630 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200827 FILED AS OF DATE: 20200831 DATE AS OF CHANGE: 20200831 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ARMISTICE CAPITAL, LLC CENTRAL INDEX KEY: 0001601086 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-25466 FILM NUMBER: 201153032 BUSINESS ADDRESS: STREET 1: 510 MADISON AVENUE, 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 231-4932 MAIL ADDRESS: STREET 1: 510 MADISON AVENUE, 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Armistice Capital Master Fund Ltd. CENTRAL INDEX KEY: 0001633584 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-25466 FILM NUMBER: 201153033 BUSINESS ADDRESS: STREET 1: C/O ARMISTICE CAPITAL, LLC STREET 2: 510 MADISON AVENUE, 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 212-231-4932 MAIL ADDRESS: STREET 1: C/O ARMISTICE CAPITAL, LLC STREET 2: 510 MADISON AVENUE, 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Boyd Steven CENTRAL INDEX KEY: 0001706140 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-25466 FILM NUMBER: 201153034 MAIL ADDRESS: STREET 1: 510 MADISON AVENUE, 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cyclo Therapeutics, Inc. CENTRAL INDEX KEY: 0000922247 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] IRS NUMBER: 593029743 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6714 NW 16TH STREET, SUITE B CITY: GAINSVILLE STATE: FL ZIP: 32653 BUSINESS PHONE: 386-418-8060 MAIL ADDRESS: STREET 1: PO BOX 1180 CITY: ALACHUA STATE: FL ZIP: 32616-1180 FORMER COMPANY: FORMER CONFORMED NAME: CTD HOLDINGS INC DATE OF NAME CHANGE: 20000913 FORMER COMPANY: FORMER CONFORMED NAME: CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC DATE OF NAME CHANGE: 19941012 4 1 ownership.xml X0306 4 2020-08-27 0 0000922247 Cyclo Therapeutics, Inc. CTDH 0001601086 ARMISTICE CAPITAL, LLC 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022 0 0 1 0 0001633584 Armistice Capital Master Fund Ltd. C/O DMS CORPORATE SERVICES LTD. 20 GENESIS CLOSE, P.O. BOX 314 GRAND CAYMAN E9 KY1-1104 CAYMAN ISLANDS 0 0 1 0 0001706140 Boyd Steven C/O ARMISTICE CAPITAL, LLC 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022 0 0 1 0 Common Stock, par value $.0001 per share 2020-08-27 4 S 0 55263 0.12 A 18971787 D Common Stock, par value $.0001 per share 2020-08-27 4 S 0 0 0 A 18971787 I See Footnote Common Stock, par value $.0001 per share 2020-08-28 4 S 0 75000 0.11 A 18896787 D Common Stock, par value $.0001 per share 2020-08-28 4 S 0 0 0 A 18896787 I See Footnote Common Stock, par value $.0001 per share 2020-08-31 4 S 0 35000 0.11 A 18861787 D Common Stock, par value $.0001 per share 2020-08-31 4 S 0 0 0 A 18861787 I See Footnote Warrants 0.27 2019-05-31 2024-11-30 Common Stock 12000000 12000000 D Warrants 0.27 2019-05-31 2024-11-30 Common Stock 12000000 12000000 I See Footnote Warrants 0.15 2020-08-27 2027-08-27 Common Stock 10000000 10000000 D Warrants 0.15 2020-08-27 2027-08-27 Common Stock 10000000 10000000 I See Footnote The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"). The reported securities may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of the Master Fund. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC. Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. This constitutes the weighted average purchase price. The prices ranged from $0.11 to $0.12. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the Common Stock, par value $.0001 per share, following such exercise. Armistice Capital, LLC By: /s/ Steven Boyd, Managing Member 2020-08-31 Armistice Capital Master Fund Ltd.By: /s/ Steven Boyd, Director 2020-08-31 /s/ Steven Boyd 2020-08-31